MedTrace Logo

Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients

NCT00422617 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2007-01-17

No results posted yet for this study

Summary

An open-label, multicentre study to evaluate the efficacy and safety of one course of weekly intramuscular administration of Amevive in Taiwan patients with chronic plaque psoriasis

Conditions

  • Chronic Plaque Psoriasis

Interventions

DRUG

Alefacept (Amevive)

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Uni-Pharma

    lead INDUSTRY

Principal Investigators

  • Po-Han Huang · CGMH

Study Design

Allocation
NON_RANDOMIZED
Purpose
ECT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Completion
2005-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00422617 on ClinicalTrials.gov